Mode
Text Size
Log in / Sign up
Phase 3 Completed N=98 Randomized Treatment

Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children

Source: ClinicalTrials.gov NCT02879747 ↗
Enrolled (actual)
98
Serious AEs
10.2%
Results posted
Apr 2019
Primary outcomePrimary: The Proportion of Children Maintaining Normal Growth Velocity — 23; 32; 31 Participants
◆ Published Evidence
Established
84citations · ~5 / year
Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
The Journal of clinical endocrinology and metabolism · 2009 · Open access · High-confidence link

Summary

The objective was to study whether normal growth velocity can be maintained with adapted GH dosage in GH treated prepubertal children who have responded to GH treatment with fulfilled catch up growth (=difference to target height reached, less than - 0.6 SDS).

Linked Publications (3)

  • Growth hormone (GH) dosing during catch-up growth guided by individual responsiveness decreases growth response variability in prepubertal children with GH deficiency or idiopathic short stature.
    The Journal of clinical endocrinology and metabolism · 2009 · 84 citations · Open access · High-confidence link
  • GH Dose Reduction Maintains Normal Prepubertal Height Velocity After Initial Catch-Up Growth in Short Children.
    The Journal of clinical endocrinology and metabolism · 2019 · 4 citations · Open access · Likely link
  • Interpreting IGF-1 in children treated with recombinant growth hormone: challenges during early puberty.
    Frontiers in endocrinology · 2024 · 3 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
The Proportion of Children Maintaining Normal Growth Velocity
23; 32; 31
SECONDARY
IGF-I
-1.10; 0.58; -0.06
SECONDARY
Height SDS at Start of Puberty
-1.0; -1.06; -0.98

Eligibility Criteria

Inclusion Criteria

  • Participated in the 'GH-dose catch-up study' 98- 0198-003.
  • Midparental height reached (difference less than 0.6 SDS)
  • Prepubertal at start of the study (girls =B 1, boys: testes : breast stage 2, or testes > 4ml).
  • Poor compliance.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02879747) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search